Actively Recruiting
Comparison of Recurrence Between Mini-SLET and Limbal-Conjunctival Autograft Techniques in Primary Pterygium
Led by Instituto de Oftalmología Fundación Conde de Valenciana · Updated on 2024-05-07
68
Participants Needed
1
Research Sites
79 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The surgical treatment options for pterygium, an abnormal growth on the eye's frontal surface can be treated with several surgical techniques. The rates of pterygium coming back varies depending on the surgical technique employed and other factors related to the patient and surgery. The objective of this study is to assess the efficacy and safety of incorporating a single amniotic membrane with stem cells in the treatment of primary pterygium, aiming to enhance surgical outcomes and minimize recurrence rates.
CONDITIONS
Official Title
Comparison of Recurrence Between Mini-SLET and Limbal-Conjunctival Autograft Techniques in Primary Pterygium
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with primary nasal pterygium > 2mm
- Patients who can present and continue follow-up for the duration of the study
- Acceptance to participate in the study by signing the informed consent.
You will not qualify if you...
- Patients with rheumatoid arthritis
- Collagenopathy
- Pregnant
- Infection, conjunctival inflammation or ocular trauma
- Glaucoma
- Previous ocular surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Instituto de oftalmología conde de Valenciana
Mexico City, Mexico, 06800
Actively Recruiting
Research Team
E
Enrique Graue Hernandez
CONTACT
N
Nicolas Kahuam Lopez
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here